Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. 10, 766-779, November 2005; doi:10.1634/theoncologist.10-10-766
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cianfrocca, M.
Right arrow Articles by Gradishar, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cianfrocca, M.
Right arrow Articles by Gradishar, W. J.

Controversies in the Therapy of Early Stage Breast Cancer

Mary Cianfrocca, William J. Gradishar

Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA

Key Words. Drug therapy • adjuvant • Breast neoplasms • Chemotherapy, adjuvant • Antineoplastic agents, hormonal

Correspondence: William J. Gradishar, M.D., Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 N. St. Clair, Suite 850, Chicago, Illinois 60611, USA. Telephone: 312-695-4125; Fax: 312-695-6189; e-mail: w-gradishar{at}northwestern.edu

Breast cancer is the most common malignancy among U.S. women, with more than 200,000 new cases diagnosed annually. In the U.S., mortality from breast cancer has declined in recent years as a result of more widespread screening, leading to earlier detection, as well as advances in the adjuvant treatment of early-stage disease. It is widely accepted that the appropriate use of adjuvant chemotherapy and endocrine therapy improves the disease-free and overall survival of patients with early-stage breast cancer. It is, therefore, standard clinical practice to administer adjuvant systemic therapy to patients with node-positive and high-risk, node-negative breast cancer. There remain, however, many controversies in the primary systemic therapy of breast cancer, which are discussed in this review.




This article has been cited by other articles:


Home page
 The OncologistHome page
G. Ferretti, A. Felici, P. Papaldo, P. Carlini, A. Fabi, and F. Cognetti
Trastuzumab Combined with Paclitaxel after Doxorubicin and Cyclophosphamide for Operable HER2-Positive Breast Cancer.
Oncologist, May 1, 2006; 11(5): 533 - 533.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2005 by AlphaMed Press.
Advertisement